December 1, 2021EP Europace
Implantable cardioverter-defibrillators for hypertrophic cardiomyopathy: The Times They Are a-Changin’
Key result
Individualized S-ICD versus TV-ICD selection minimizes device complications in HCM.
Why the study?
Clinical heterogeneity in HCM and the availability of distinct ICDs highlight the need to tailor device selection to preserve survival benefit while avoiding device-related complications.
Population
Patients with hypertrophic cardiomyopathy (HCM) at high risk of sudden cardiac death
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Individualized ICD selection may reduce complications in hypertrophic cardiomyopathy; leaves open need for randomized subcutaneous versus transvenous comparisons.
Structured PICO
P
Population
Patients with hypertrophic cardiomyopathy (HCM) at high risk of sudden cardiac death
I
Intervention
Implantable cardioverter-defibrillator (ICD)
Highlights the importance of tailored ICD selection in patients with hypertrophic cardiomyopathy to balance survival benefits against device-related complications.
Limitations
- Lack of specificity in current sudden cardiac death risk assessment strategies
- False-positive prediction of ineligibility by current S-ICD screening tools
- Potential for accelerated battery depletion in specific S-ICD models
Cite This Study
Francia et al. (2021) conducted a review in Hypertrophic cardiomyopathy. Implantable cardioverter-defibrillators (ICDs) was evaluated. In patients with hypertrophic cardiomyopathy, individualized selection between subcutaneous and transvenous implantable cardioverter-defibrillators is necessary to minimize device-related complications.